In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system

Artif Organs. 2003 Feb;27(2):188-92. doi: 10.1046/j.1525-1594.2003.t01-2-06993.x.

Abstract

The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond-like carbon (DLC) coating. Four calves were implanted with the MPC polymer-coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 +/- 37.2% (5-85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 +/- 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Physiological Phenomena
  • Carbon
  • Cattle
  • Coated Materials, Biocompatible* / adverse effects
  • Heart-Assist Devices* / adverse effects
  • Methacrylates* / adverse effects
  • Phosphorylcholine* / adverse effects
  • Phosphorylcholine* / analogs & derivatives*
  • Thrombosis / etiology

Substances

  • Coated Materials, Biocompatible
  • Methacrylates
  • Phosphorylcholine
  • 2-methacryloyloxyethyl phosphorylcholine
  • Carbon